X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BHV2000 (taldefgrobep-alpha) is a fully human anti-myostatin recombinant protein that lowers free myostatin and acts as an Activin 2b receptor antagonist with the myostatin-taldefgrobep complex, thereby blocking myostatin signaling in skeletal muscles.
Lead Product(s): Taldefgrobep-alfa
Therapeutic Area: Genetic Disease Product Name: BHV2000
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2023
Details:
BHV-7000 (formerly known as KB-3061). BHV-7000 is a potent activator of Kv7.2/Kv7.3, which are key subunits involved in neuronal signaling and in regulating the hyperexcitable state in focal epilepsy.
Lead Product(s): BHV-7000
Therapeutic Area: Neurology Product Name: BHV-7000
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
BHV2000 (taldefgrobep-alpha) is a fully human anti-myostatin recombinant protein that lowers free myostatin and acts as an Activin 2b receptor antagonist with the myostatin-taldefgrobep complex, thereby blocking myostatin signaling in skeletal muscles.
Lead Product(s): Taldefgrobep-alfa
Therapeutic Area: Genetic Disease Product Name: BHV2000
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
BHV-7000 (formerly known as KB-3061). BHV-7000 is a potent activator of Kv7.2/Kv7.3, which are key subunits involved in neuronal signaling and in regulating the hyperexcitable state in focal epilepsy.
Lead Product(s): BHV-7000
Therapeutic Area: Neurology Product Name: BHV-7000
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
Vydura (also known as Rimegepant) is an oral lyophilisate and is the first calcitonin gene-related peptide (CGRP) receptor antagonist migraine therapy to be accepted by the SMC.
Lead Product(s): Rimegepant Sulfate
Therapeutic Area: Neurology Product Name: Vydura
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
Under the agreement, Biohaven and Highlightll will coordinate clinical development across global regions for BHV-8000 (previously TLL-041), an oral, brain-penetrant, dual inhibitor of TYK2 and JAK1 for the treatment of brain disorders.
Lead Product(s): BHV-8000
Therapeutic Area: Neurology Product Name: BHV-8000
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Hangzhou Highlightll Pharmaceutical
Deal Size: $970.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement March 22, 2023
Details:
BHV2000 (taldefgrobep-alpha) is a fully human anti-myostatin recombinant protein that lowers free myostatin and acts as an Activin 2b receptor antagonist with the myostatin-taldefgrobep complex, thereby blocking myostatin signaling in skeletal muscles.
Lead Product(s): Taldefgrobep-alfa
Therapeutic Area: Genetic Disease Product Name: BHV2000
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
The acquisition brings to Pfizer a portfolio of promising calcitonin gene-related peptide (CGRP) receptor antagonists including NURTEC® ODT (rimegepant), to address needs of millions of migraine patients worldwide.
Lead Product(s): Rimegepant Sulfate
Therapeutic Area: Neurology Product Name: Nurtec ODT
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $11,600.0 million Upfront Cash: $11,600.0 million
Deal Type: Acquisition October 03, 2022
Details:
Taldefgrobep alfa (also known as BMS-986089) is a modified adnectin designed to specifically bind to myostatin, a fully human anti-myostatin recombinant protein that lowers free myostatin and acts as an Activin 2b receptor antagonist with myostatin-taldefgrobep complex.
Lead Product(s): Taldefgrobep Alfa
Therapeutic Area: Genetic Disease Product Name: BMS-986089
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
Biohaven's troriluzole and Vigeo's VT1021 are entering the GBM AGILE trial, which initially opened in July 2019 and has screened over 1200 patients to date. Troriluzole and VT1021 will enroll patients with newly-diagnosed and recurrent glioblastoma.
Lead Product(s): VT1021
Therapeutic Area: Oncology Product Name: VT1021
Highest Development Status: Phase II/ Phase IIIProduct Type: Peptide
Recipient: Vigeo Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
